Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo

Yervoy/Opdivo combo proves significant survival benefit over Yervoy alone in Phase III frontline melanoma study, but is on par with Opdivo alone in patients with higher PD-L1 expression.

T-cells attacking cancer_1200x675

Survival data for Bristol-Myers Squibb Co.'s Yervoy/Opdivo combination in the CheckMate 067 study in frontline melanoma reinforce the regimen's potency, but also revive a debate about whether the regimen should be reserved for select subsets of patients, with others getting enough benefit from Opdivo alone or other treatment options.

The combination of Yervoy (ipilimumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor, received accelerated approval from FDA in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category